Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback